Cancer - Immuneering Corp.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06208124

A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

Drug

IMM-6-415

Condition

Histologically or cytologically confirmed diagnosis of one of the following locally advanced unresectable or metastatic solid tumor malignancies: PDAC, RASmut melanoma, Class I BRAFmut melanoma, RASmut NSCLC, other RASmut GI cancers (aside from colorectal